Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UKI8
UPID:
TLK1_HUMAN
Alternative names:
PKU-beta; Tousled-like kinase 1
Alternative UPACC:
Q9UKI8; B3KR15; B4DX87; Q14150; Q8N591; Q9NYH2; Q9Y4F6
Background:
Serine/threonine-protein kinase tousled-like 1, known as PKU-beta and Tousled-like kinase 1, plays a crucial role in DNA repair and cell cycle regulation. It is rapidly and transiently inhibited by phosphorylation following DNA double-stranded breaks during S-phase, indicating its involvement in the ATM-pathway dependent cell cycle checkpoint. This kinase also phosphorylates histone H3 at 'Ser-10', contributing to chromatin assembly processes.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase tousled-like 1 could open doors to potential therapeutic strategies.